De Novo
DEN240062: Minder System
FDA De Novo · epi-minder pty ltd · decided Apr 17, 2025
Key facts
| De Novo number | DEN240062 |
|---|---|
| Device name | Minder System |
| Applicant | epi-minder pty ltd |
| Product code | SEM |
| Date received | Oct 18, 2024 |
| Decision date | Apr 17, 2025 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Neurology |
| FEI number | 3039411139 |
At a glance
- 1–9 Later 510(k)s citing this De Novo
- 10–99 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: